Curious about best perceived restructuring shops on the Street. Maybe in terms of deal flow, current momentum, exit ops, pay. Any perceptions are appreciated.
| +249 | Earliest you can get fired | 46 | 4h |
| +244 | UBS’s M&A BANKERS ARE DOING TERRIBLY. $200M EXTRA IS BEING CUT | 41 | 4h |
| +236 | Are target prospects getting dumber? | 46 | 5m |
| +228 | MBB Pay Raises | 47 | 4h |
| +212 | Career Crossroads | 25 | 4h |
| +208 | US 2027 SA IB worried about background check | 48 | 44m |
| +195 | Investment Banking is Divine | 33 | 4h |
| +192 | Analyst: Why is UBS IB doing worse than peers?, UBS CFO: No Comment | 38 | 4h |
| +191 | How do YOU manage networking requests? | 28 | 4h |
| +189 | Another $115bn Mega deal for these banks. Congrats! | 42 | 1h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
PJT - probably the top shop on the street
Lazard / Evercore / HL - All very good and have solid deal flow and exits. Heard really good things about work life balance at HL
Millstein - heard really good things (comp was apparently top notch)/was up and coming but idk how the gugg acquisition changes things
Lazard’s deal flow has been strong these days - where are the analysts going?
I've heard of people being wheeled out of HL London by paramedics after collapsing. Former colleague who worked there had 2 free weekends in 3 years.
Sorry comments applied to NYC only, no idea on other locations
Do you know how they pay in Europe? Their team in Europe seems to be very small.
What are some general personalities that work in RX? Aren't you dealing with some pretty tough situations?
As mentioned. Best analysts roles for Rx with top pay, prestige, and exits are PJT and EVR. Most well-known analyst programs that specialize in Rx are PJT/EVR/HL. HL also very good. Lazard's group is also great but the analyst role is M&A/Rx. Exits from all these groups are fantastic.
This is inaccurate regarding Lazard's program. They split their Industry (usually M&A) and Rx practices into separate groups, though sometimes a deal works through more than one group (e.g. I think the Toys bankruptcy was worked on by both the consumer and Rx groups). So the Rx analyst program is actually separate from M&A.
Clearly you work for EVR. No one lumps their rx practice with other top rx practices. Also, recently analyst placement has not been too great. Their bread and butter is m&a
Jeez.. pretty harsh response. Their Rx analyst placement has been fantastic so not really sure what you are talking about. Also, the comment about Lazard is inaccurate as they also have placed very well in recent years.
Doesn't get as much love on this site because the analyst program isn't dedicated restructuring, which makes sense given the audience of WSO, but Moelis has killed restructuring in 2018. I'm positive they're first place in the bankruptcy league table by value, and maybe second by the number of engagements.
All the above listed are great shops. Some like Lazard are more debtor focussed vs HL which does more creditor work. As a rule of thumb, every firm does both, but different firms focus their practices differently. Debtor engagements tend to pay higher fees but in a restructuring, there's one debtor and often many creditors, so obviously fewer opportunities for debtor-side work.
The NYC bankruptcy world is very small. You see the same bankers and lawyers over and over again.
Also doesn’t get much love here, but Rothschild is strong. Know people currently at Moelis and Rothschild who are on some killer mandates.
Guggenheim might be one to keep an eye out for going forward.
Most of the senior team at Rothschild left
Deleted
Look at the Thomson Reuters league tables (ignore non-investment banks).
Q3 18: https://ibb.co/pQX6Zyn https://ibb.co/d7TwP4x
FY 17: https://ibb.co/qkmFSpc https://ibb.co/7KdDYvp
Deleted
Question: why ignore the non investment banks? Do they do something else? If so, why are they on the same league tables?
They don't do the same work as investment banks from a restructuring perspective. The consulting firms you see on the list typically focus on operational restructuring whereas the banks focus on financial restructuring. As a company, it is very common to hire both an operational advisor (an Alix/A&M/FTI/Zolfo) and a financial advisor (Laz/Moelis/HL/PJT).
Good stuff. Would agree with the above in terms of exit opps for best analyst classes (PJT/EVR/HL) but interesting to see recent deals being done at diff firms. Jefferies is another good shop that rarely gets mentioned
HL RX has placed well in LA from my understanding. Given their specialty in creditor side advisory, their analysts are exposed to numerous credit funds which bodes well for them. Furthermore, creditor side roles are less intense compared to debtor side roles. You will often times see Analysts balancing 4 or more creditor rx deals (more facetime with creditors) while debtor advisory may require an analysts full attention. I have always found debtor side advisory roles to be more fulfilling.
-XSX
HL RX kills it. Moelis kills it. EVR kills it. PJT/LAZ kill it. They all place very well. Tbh any rx shop will kill it over the next few years as maturities need to be extended and overlevered sponsor backed companies file. Can't imagine a better group to be in given the current environment.
I would disagree with your last given the following: 1.) Given the rising rate environment and brexit warnings since 2016, a lot of the refinancings and maturity extensions have already been executed in 2017 / 2018 2.) The vast majority (i'm talking like 85%+) of leveraged loans have been issued as covenant-lite or some sort of "covenant-loose" with a ridiculous headroom (think of like 40%+ assuming full RCF is drawn) so I would expect covenant breaches will be a lot lesser than you normally expect, even assuming we've reached the peak of the credit cycle and things head south starting next year
I do agree with your RX bank list - usually some combination of PJT / LAZ / HLHZ / EVR / Moelis when it comes to straight up dealflow. On a side note, some of the smartest kids I've ever met worked at PJT RX and Ducera RX, and they both absolutely loved their experiences for what it's worth.
Expect a lot more creditor fights and litigious deals as a result of all of these covenant-lite loans
What has EVR done that gets them a good reputation? I remember they got TXU but I thought perception was they didnt do the best job there (personally no opinion)
In terms of an overall practice I dont think they rank with Laz/HL/PJT but I guess the analyst program is different? Where have analysts landed from EVR Rx?
Dolorum nihil cupiditate aut voluptatibus. Dolores porro accusamus enim id. Illo totam eius est tempore doloremque. Eius dolor deserunt est. Soluta aliquam consequatur et voluptate voluptas nisi facere vitae.
Quod porro doloremque dolorum est. Deserunt similique odio pariatur ipsam. Quia eaque optio voluptatem soluta qui aut.
Id ut adipisci et ea qui. Cumque sit maiores omnis sint. Aut suscipit voluptatem in. Quis cupiditate dolorem qui et nostrum.
Ut est beatae assumenda qui molestias amet numquam. Eum at et sint quod. Nulla perferendis repudiandae atque quos provident.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Dolorem animi ducimus dolorem et. Quia natus ut distinctio beatae dolores et recusandae. Aut qui exercitationem voluptatibus error. Dolorem fuga rerum voluptate voluptas beatae. Laudantium animi fuga cumque. Quibusdam non nihil et ab doloribus ex. Sed eaque laboriosam et et id ratione perferendis.
Necessitatibus ut veniam provident voluptatem expedita. Blanditiis aliquid pariatur ex voluptas. Consequatur fuga provident neque voluptatem laborum modi. Quia doloribus dicta et dolor nihil. Quia autem aliquid reprehenderit blanditiis.